NCT05586633

Brief Summary

Low back pain is a common disorder that every individual in the society is likely to meet throughout his/her life. Low back pain lasting longer than 12 weeks is defined as chronic low back pain and causes serious disability in the community. Conservative, pharmacological, interventional and surgical treatment options are available in its treatment. In this study, it was aimed to determine the effects of ultrasound-guided deep paravertebral periforaminal ozone injection treatment on physical examination, functional independence, quality of life and pain scores in patients with chronic low back and leg pain and to compare it with transforaminal epidural steroid injection treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2021

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

August 14, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 19, 2022

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

October 19, 2022

Status Verified

October 1, 2022

Enrollment Period

1 year

First QC Date

August 14, 2022

Last Update Submit

October 15, 2022

Conditions

Keywords

Low Back Painperiforaminal ozon injectiontransforaminal steroid injectionultrasound guided injection

Outcome Measures

Primary Outcomes (7)

  • PAİN-Visual Analog Scala (VAS)

    Visual Analog Scala (VAS), patients are asked to circle the number between 0 and 10 that fits best to their pain intensity. Severity of pain was assessed VAS using the standard 10 cm (back pain and leg pain) with 0 meant "no pain" at one end, and 10 meant "unbearable pain" at the other end.

    2nd week, 4th week, 8th week pain change

  • Quality of life - Short Form-36 (SF-36)

    Satisfaction assessed by the SF-36. Short Form (SF-36) was used to investigate the quality of life of the patients.The reliability and validity of the Turkish version of SF-36 has been demonstrated. SF-36 consists of 36 questions on eight different subscales including physical functioning, role limitations due to physical health problems, bodily pain, general health perceptions, energy and fatigue, vitality, social functioning, role limitations due to emotional problems and general mental health. Each subscale of SF-36 is scored between 0 and 100, and higher scores show better Quality of life.

    2nd week, 4th week, 8th week quality of life change

  • Oswestry Disability Index (ODI)

    In the ODI questionnaire, the effect of low back pain on activities of daily living is questioned. In the test, which consists of 10 questions in total, the patient's pain intensity, the effects of pain on personal care, walking, lifting weights, standing, sitting, sleeping, sexual life, social life and traveling are questioned. The patient can get a minimum of 0 and a maximum of 5 points from each question. The maximum score to be taken from the test is 50. The patient's score is found by dividing the total score of the patient by 50, which is the maximum score, and calculating the percentage. (Patient's score ÷ maximum score × 100). Accordingly, it is calculated how much the patient's life activities are affected.

    2nd week, 4th week, 8th week pain change

  • Physical examination-Lumbar joint range of motion examination

    Lumbar joint range of motion examination( flexion-extansion-lateral flexion-rotation)

    2nd week, 4th week, 8th week examination change

  • Physical examination-straight leg raise test

    straight leg raise test- It is recorded whether there is normal or abnormal

    2nd week, 4th week, 8th week examination change

  • Physical examination-femoral nerve stretch test

    femoral nerve stretch test - It is recorded whether there is normal or abnormal

    2nd week, 4th week, 8th week examination change

  • Physical examination-Walleix palpation

    Walleix palpation- It is recorded whether there is tenderness in Walleix palpation.

    2nd week, 4th week, 8th week examination change

Study Arms (2)

deep paravertebral- periforaminal ozone injection

ACTIVE COMPARATOR
Procedure: deep paravertebral periforaminal ozone injeciton

transforaminal steroid injeciton

ACTIVE COMPARATOR
Procedure: transforaminal steroid injeciton

Interventions

Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week. Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up.

deep paravertebral- periforaminal ozone injection

Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy. Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up.

transforaminal steroid injeciton

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Back and leg pain lasting longer than 3 months
  • Diagnosis of lumbar disc herniation with advanced imaging techniques after anamnesis, - physical examination and laboratory examinations
  • Continuation of complaints despite conservative treatment before
  • Regular participation in the study voluntarily

You may not qualify if:

  • Being pregnant and breastfeeding
  • History of lomber surgery
  • Peripheral neuropathy (diabetes, alcoholism...)
  • Cauda equina syndrome or progressive neurologic deficit in the lower extremity
  • Neurogenic bladder/bowel syndrome
  • Arterial vascular disease-Vascular claudication
  • Spinal stenosis, spondylolysis, spondylolisthesis
  • Local infection at the injection site
  • Presence of bleeding diathesis
  • Neuro-degenerative diseases
  • Uncontrolled diabetes, hypertension
  • History of malignancy
  • Uncontrolled psychiatric illness
  • BMI over 40
  • Allergy to injection substances

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gaziler Physical Medicine and Rehabilitation Education and Research Hospital

Ankara, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Low Back Pain

Condition Hierarchy (Ancestors)

Back PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

esra ülgen kıratlıoğlu

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 14, 2022

First Posted

October 19, 2022

Study Start

November 1, 2021

Primary Completion

November 1, 2022

Study Completion

November 1, 2022

Last Updated

October 19, 2022

Record last verified: 2022-10

Locations